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Despite the wide improvements in breast cancer (BC) detection and adjuvant treatment, BC is still responsible for
approximately 40,000 deaths annually in the United States. Novel biomarkers are fundamental to assist clinicians in
BC detection, risk stratification, disease subtyping, prediction of treatment response, and surveillance, allowing a more
tailored approach to therapy in both primary and metastatic settings. In primary BC, the development of molecular
profiling techniques has added prognostic and predictive information to conventional biomarkers - estrogen receptor,
progesterone receptor, and human epidermal growth factor receptor 2. Moreover, the application of next-generation
sequencing and reverse-phase protein microarray methods in the metastatic setting holds the promise to further
advance toward a personalized management of cancer. The improvement in our understanding on BC biology
associated with the study of the genomic aberrations characterizing the most common molecular subtypes allows us to
explore new targets for drug development. Finally, the integration of cancer stem cell-targeted therapies and immune
therapies in future combination regimens increases our chances to successfully treat a larger proportion of women with
more aggressive and resistant metastatic disease. This article reviews the current state of novel biological markers for BC,
the evidence to demonstrate their clinical validity and utility, and the implication for therapeutic targeting.Introduction
Breast cancer (BC) represents the most common cancer
among women; there were 232,670 estimated new cases
and 40,000 estimated deaths in the United States in
2014 [1]. In recent decades, the widespread use of mam-
mographic screening has increased the rate of regional
disease detection, and the development of more effective
adjuvant chemotherapeutic regimens, extended use of
endocrine therapies, and standard application of targeted
agents have all contributed to improve outcomes of
women with primary BC. However, the widespread
application of these diagnostic and therapeutic interven-
tions requires significant resources and is associated
with treatment-related morbidity; therefore, determining
the subgroup of patients who can truly benefit from the
implementation of such advanced measures is still a
challenge.
For years, researchers have investigated clinical tools
and molecular approaches with the aim of discovering a
combination of clinical and biological features that could* Correspondence: massimo.cristofanilli@jefferson.edu
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article, unless otherwise stated.predict cancer features and behavior, allowing a more
tailored approach to therapy. New biomarker develop-
ment is fundamental to assist clinicians in BC detection
and diagnosis, risk stratification, disease subtyping, pre-
diction of treatment response, and surveillance, allowing
a personalized cancer management. The integration
between novel biomarkers and routinely tested clinic-
pathological features, such as hormone receptor (HR)
and human epidermal growth factor receptor 2 (HER2)
status, may guide clinicians in systemic therapy decisions
in both primary and metastatic settings. This article re-
views the current state of novel biological markers for
BC, the evidence to demonstrate their clinical validity
and utility, and the implication for therapeutic targeting.
Breast cancer subtypes and gene expression
profile tests
From the clinical point of view, BC can be classified
according to the immunohistochemistry/fluorescence in
situ hybridization (IHC/FISH) profile and divided on the
basis of the presence of estrogen receptor (ER), proges-
terone receptor (PR), and HER2.
At the molecular level, Perou and colleagues [2] ana-
lyzed BC gene expression patterns derived from cDNACentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Toss and Cristofanilli Breast Cancer Research  (2015) 17:60 Page 2 of 11microarrays, initially identifying four major intrinsic
gene signatures: luminal, HER2-enriched, basal-like,
and normal breast-like subtype. Subsequent studies
led to the division of luminal tumors in two subgroups
(luminal A and luminal B) and demonstrated a correlation
between these gene expression patterns and survival, dis-
ease relapse, site of metastasis, and chemotherapy re-
sponse [3-5]. Over the years, other molecular subtypes
have been described, such as claudin low and molecular
apocrine tumors. In 2009, Parker and colleagues [6] devel-
oped an efficient 50-gene classifier, called Prediction
Analysis of Microarray (PAM50), that reanalyzed the
previous five subgroups defining the four major intrinsic
subtypes currently known: luminal A, luminal B, HER2-
enriched, and basal-like (Table 1).
In recent years, five novel gene expression prognostic
tests for BC have been developed: MammaPrint,
MapQuant Dx, Oncotype DX, PAM50, and Theros Breast
Cancer Index. The rationale for developing multi-gene-
based prognostic tests is not only to add prognostic and
predictive information to conventional biomarkers but to
provide more reliable and reproducible techniques than
the IHC-based assays, reducing technical errors and sub-
jective interpretation [7]. One of the first commercially
available and US Food and Drug Administration (FDA)-
approved signatures was the 70-gene MammaPrint assay,
which stratifies patients into low- or high-risk for distant
metastases at 5 years. More recently, the 21-gene
Oncotype DX assay was developed to estimate the risk of
relapse in ER+, node-negative BC and their chemo-
sensitivity. Oncotype DX divides patients into three
groups on the basis of their recurrence score (RS): low-
risk (RS of less than 18), intermediate-risk (RS of 18
to 30), or high-risk (RS of more than 31) [8]. As previously
described, the PAM50 test defined the four major intrinsic
subtypes of BC through the analysis of 50 classifier genes
and five control genes. Along with the identification ofTable 1 Breast cancer intrinsic subtypes with prevalent immu
Intrinsic subtype cDNA microarrays IHC
Luminal A The highest expression of the ER α gene,
GATA-binding protein 3, X-box-binding
protein 1, trefoil factor 3, hepatocyte
nuclear factor 3 α, and estrogen-regulated
LIV-1
ER- an
Ki-67 <
Luminal B Low to moderate expression of the
luminal-specific genes, including the
ER cluster
ER- an
with K
ER- an
with a
HER2-enriched High expression of several genes in the
ERBB2 amplicon at 17q22.24, including
ERBB2 and GRB7
ER- an
Basal-like High expression of keratins 5 and 17,
laminin, and fatty acid-binding protein 7
ER- an
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immusubtypes, PAM50 has been shown to be an independent
predictor of survival in BC [9]. PAM50 generates a numer-
ical score (risk of recurrence, or ROR) that along with
clinical features estimates the risk of relapse at 10 years in
postmenopausal women with stage I/II node-negative or
stage II node-positive (one to three positive lymph nodes)
and HR-positive BC [10].
In patients with ER-positive and node-negative early
BC, the PAM50 platform has been demonstrated to pro-
vide more prognostic information than the Oncotype
DX test, since PAM50 was better able to distinguish be-
tween intermediate- and high-risk patients [11]. On
these bases, the platform was recently cleared by the
FDA. Notably, in the same study, PAM50 and Oncotype
DX assays were compared with the IHC4 score. IHC4 is
a prognostic model that combines quantitative IHC
measures of ER, PR, HER2, and Ki-67 performed in
high-quality laboratories. In this study, relatively similar
information was provided by ROR and IHC4 in all pa-
tients, but in the HER2-negative/node-negative sub-
group, ROR was more informative than IHC4 [11].
The other multi-gene-based assays showed similar
prognostic performances, and their prognostic value is
due mainly to the ability of providing a robust measure-
ment of proliferation activity, particularly in ER+/HER2−
patients [12]. However, only the Oncotype Dx assay
achieved level IB evidence and has been incorporated
into current National Comprehensive Cancer Network
and American Society of Clinical Oncology guidelines,
since it demonstrated a role as a predictive test in two
prospectively designed retrospective studies with tumor
specimens obtained from randomized clinical trials
comparing tamoxifen with or without chemotherapy
[13]. The evaluation and the comparison between the
predictive value of PAM50 and Oncotype DX are ongoing
in the prospective RxPONDER trial (NCT01272037), and
results from the prospective MINDACT (NCT00433589)no-histochemical profiles and options of treatment [3]
Treatment
d/or PR-positive HER2-negative
14%
Endocrine therapy (chemotherapy
for selected patients)
d/or PR-positive HER2-negative
i-67≥ 14%
Endocrine therapy ± chemotherapy
d/or PR-positive HER2-positive
ny Ki-67
Chemotherapy + anti-HER2 therapy +
endocrine therapy
d PR-negative HER2-positive Chemotherapy + anti-HER2 therapy
d PR-negative HER2-negative Chemotherapy
nohistochemistry; PR, progesterone receptor.
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direct evidence of the predictive value in the adjuvant
setting of, respectively, MammaPrint and Oncotype DX
assays.
Through multi-gene profiling tools, more information
can be obtained from tumor tissues. For instance, the
PAM50 platform provides quantitative values for prolif-
eration, luminal gene expression, estrogen receptor 1
(ESR1), progesterone receptor gene (PGR), and HER2.
Moreover, on the same tissue used for MammaPrint, the
BluePrint test can be performed. BluePrint is a molecu-
lar subtyping assay that analyzes the mRNA levels of 80
additional genes to better discriminate among the mo-
lecular subtypes. Combining MammaPrint and BluePrint
allows patients to be stratified into luminal-type/
MammaPrint low-risk (similar to luminal A), luminal-type/
MammaPrint high-risk (similar to luminal B), HER2-type,
and basal-type [14]. This stratification has demonstrated
several implications in neoadjuvant trials. The recent
CTNeoBC pooled analysis of 12 neoadjuvant randomized
trials highlighted that patients who achieve a pathologic
complete response (pCR) show more favorable outcomes.
Notably, the achievement of pCR varied according to BC
subtype, and the prognostic value was greatest in more ag-
gressive subtypes. In particular, the association between
pCR and long-term outcomes was strongest in patients
with HR+/HER2−/grade 3 tumors, triple negative breast
cancer (TNBC), and HR−/HER2+ who received trastuzu-
mab [15]. Interestingly, Glück and colleagues [16] investi-
gated the correlation between pCR rate after neoadjuvant
chemotherapy (NACT) and long-term outcome comparing
BluePrint and MammaPrint combined model versus clin-
ical subtyping using IHC/FISH. This study confirmed theTable 2 Main features of the principal available multi-gene as
Assay MammaPrint Oncotype D
Number of genes 70 21
Sample Tissue core of fresh specimens preserved
in RNA later or fresh-frozen tissue
Formalin-fixe
or fresh-froze
Technique DNA microarray Quantitative
Study population Patients <61 years, with T1-T2, N0
disease (largely ER-positive)
Patients with
disease
Output Low- or high-risk patients Recurrence sc
Guidelines FDA-approved National Com
American So
Clinical applications Accurate and reproducible representation
of BC biological features [7]. Overall risk
assessment of BC recurrence [8]. BluePrint
and MammaPrint improve stratification of
patients in the neoadjuvant setting [14,16].
Accurate and
of BC biolog
assessment o
role in tamox
positive node
efficacy in ER
patients [13].
ER-positive, n
BC, breast cancer; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; DFS, d
cyclophosphamide; FDA, US Food and Drug Administration; OS, overall survival; PAnotable benefit in response to neoadjuvant treatment, and
thus in the long-term outcome, of patients with HER2-
type and basal-type. Overall, BluePrint with MammaPrint
molecular subtyping was shown to improve the stratifi-
cation of patients in the neoadjuvant setting, improving
prognostic estimation versus IHC/FISH [16]. Thus, mo-
lecular signatures provide a more accurate representa-
tion of BC biological features, allowing prognostication
at the time of initial diagnosis, prediction of benefit
from adjuvant therapy, and response to NACT (Table 2).
Nevertheless, despite their demonstrated efficacy, there
are still large geographic differences in the adoption of
these tests, probably reflecting variations in economies,
health systems, and physician training. Therefore, in
many institutions, clinical and immunohistochemical
evaluation remains the reference method for the classi-
fication of BC.
Genomic aberrations in breast carcinogenesis as
therapeutic targets
Luminal subtypes and the PI3K/AKT/mTOR pathway
Luminal subtypes are characterized by the expression of
ER and represent a heterogeneous category in terms of
gene expression and clinical outcomes. The principal
characteristic of this group is the luminal expression sig-
nature, composed of ESR1, GATA3, FOXA1, XBP1, and
cMYB. The most frequent mutations in the luminal A
subtype are PIK3CA (45%), MAP3K1 and GATA3 (13%
each), TP53 (12%), and CDH1 (9%). The most frequent
mutations in luminal B tumors are TP53 and PIK3CA
(29% each), GATA3 (13%), and TTN (12%) gene muta-
tions (Table 3) [17,18]. In addition to TP53 mutations,
frequently within luminal B subtypes, several othersays in breast cancer
X PAM50
50 + 5 control genes
d, paraffin- embedded tissue,
n tissue
Formalin-fixed, paraffin- embedded tissue,
or fresh-frozen tissue
PCR Quantitative PCR and nCounter technology
ER-positive, node-negative Patients with stage I to III breast cancer
ore: low, intermediate, or high Risk of recurrence: low, medium, or high
prehensive Cancer Network,
ciety of Clinical Oncology
FDA-cleared
reproducible representation
ical features [7]. Overall risk
f BC recurrence [8]. Prognostic
ifen-treated patients with
s [13]. Prediction of CMF
-positive, node-negative BC
Prediction of FAC efficacy in
ode-positive BC patients [7].
Accurate and reproducible representation
of BC biological features [7]. Categorization
of tumors into the four intrinsic subtypes
[8,9]. Prediction of DFS and OS [9]. Estimate
of the risk of relapse at 5 to 15 years in
ER-positive, node-positive and -negative BC
[10]. Prediction of benefit of tamoxifen in
pre-menopausal patients [9].
isease-free survival; ER, estrogen receptor; FAC, fluorouracil, doxorubicin, and
M50, Prediction Analysis of Microarray; PCR, polymerase chain reaction.
Table 3 The most frequently mutated genes in each
molecular subtype [17,18]
Luminal A Luminal B HER2-enriched Basal-like
PIK3CA 45% PIK3CA 29% TP53 72% TP53 80%
MAP3K1 13% TP53 29% PIK3CA 39% TTN 19%
GATA3 13% GATA3 13% MUC16 14% USH2A 11%
TP53 12% TTN 12% LRP1 8% FLG 7%
CDH1 9% RYR2 7% ERBB3 8% MUC16 7%
TTN 9% RELN 5% DNAH11 8% PIK3CA 7%
MLL3 7% FAT3 5% LRP2 8% MUC17 6%
MAP2K4 6% MLL3 5% TTN 8% DNAH7 5%
NCOR1 5% MUC16 5% ATP1A4 7% FAT3 5%
AKT1 4% KCNB2 4% KIAA1109 7% SYNE1 5%
PTEN 4% MAP3K1 4% CACNA1E 7% DST 5%
HER2, human epidermal growth factor receptor 2.
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way, including ATM loss and MDM2 amplification.
The PI3K/AKT/mTOR pathway and its crosstalk with
the RAS/RAF/MEK/MAPK pathway play a crucial role
in cancer cell growth, survival, differentiation, and prolif-
eration (Figure 1). Moreover, the PI3K/AKT/mTOR
pathway participates in the complex control of cellular
energy, glucose metabolism, senescence and angiogen-
esis, and in ER-positive BC cells promotes ER transcrip-
tional activity. The protein kinases involved in these
pathways represent attractive and promising drug targets
for BC treatment, and several molecules have already
been developed in pre-clinical and clinical trials.
Although anti-estrogen therapies have been shown to
reduce the risk of disease recurrence in ER-positive BC,
a significant number of patients express de novo or ac-
quired resistance to endocrine therapy. To date, multiple
mechanisms responsible for endocrine resistance have
been described, including the amplification or overex-
pression of the HER2 proto-oncogene and the hyperacti-
vation of the PI3K/AKT/mTOR pathway [19]. The most
common mutations or amplifications in the PI3K/AKT/
mTOR pathway affect the genes encoding the PI3K cata-
lytic subunits (PIK3CA, PIK3CB), PI3K regulatory sub-
unit (PIK3R1), receptor tyrosine kinases (HER2, FGFR1),
K-Ras, PI3K effectors (AKT1, AKT2, PDK1), and loss of
PTEN and INPP4B [20]. The activation of this parallel
pathway may provide alternative proliferation and sur-
vival stimuli to cancer cells, even in the presence of in-
hibition in the ER pathway. On this basis, recent clinical
trials investigated simultaneous targeting of the PI3K/
AKT/mTOR and ER pathways. In particular, the mTOR
inhibitor everolimus (Afinitor) in combination with the
aromatase inhibitor exemestane was shown to improve
survival in patients with metastatic ER-positive BC after
progression on prior endocrine treatment [21]. Othermechanisms of resistance to endocrine therapies include
the dysregulation of normal cell cycle control. In par-
ticular, cyclin D1 and cyclin-dependent kinase (CDK) 4/
6 cooperate to phosphorylate and inactivate the retino-
blastoma tumor-suppressor protein (RB), allowing cell
cycle progression even in BC cells with efficient inhib-
ition of ER [22]. Recently, the final results of the phase
II PALOMA-1 trial (NCT00721409) reported a statisti-
cally significant improvement in progression-free sur-
vival (PFS) with the addition of a specific inhibitor of
CDK 4/6 activity (palbociclib) to letrozole compared
with letrozole alone (20.2 versus 10.2 months). The over-
all survival (OS) analysis showed a trend in favor of
combined treatment but was not statistically significant
[23]. On these bases, palbociclib and other CDK 4/6
inhibitors, including LEE011 and abemaciclib, are cur-
rently under investigation in several phase III clinical
trials.
Genetic mutations and major structural defects in the
DNA strands may permanently compromise gene func-
tion. In contrast, epigenetic aberrations can keep the
gene structure intact and can be partially or completely
reverted, restoring the original gene conformation.
These transient modifications are dynamically estab-
lished by enzymes which respond to intrinsic and extrin-
sic stimuli, and include methylation, histone acetylation,
phosphorylation, ubiquitination, citrullination, sumoyla-
tion, and ADP ribosylation. In the last decade, several
therapies targeting epigenetic modifying enzymes have
been developed, and the FDA has approved azacitidine
and decitabine for high-risk myelodysplastic syndrome
and two histone deacetylase (HDAC) inhibitors (vorino-
stat and romidepsin) for cutaneous T-cell lymphoma
[24]. For what concerns BC, recent research highlighted
that DNA methylation may influence the tumor receptor
status. In particular, ER positivity is linked to the methy-
lation of specific genes, including RASSF1A, CCND2,
GSTP1, and TWIST. Vesuna and colleagues [25] re-
ported that TWIST, a gene overexpressed in high-grade
BC, promotes downregulation of ER through the recruit-
ment of HDAC1 and reduced expression of ER through
the recruitment of DNMT3B. On this basis, azacitidine
and valproic acid (HDAC inhibitor) have been investi-
gated in this setting and showed the capability of par-
tially restoring ER expression [25]. Moreover, in the
ENCORE 301 study (NCT00676663) [26], entinostat was
shown to restore sensitivity to hormonal therapy and to
improve PFS and OS when given in combination with
exemestane in patients with ER-positive advanced BC re-
sistant to previous aromatase inhibitors. On the basis of
this phase II trial, entinostat received a Breakthrough
Therapy designation from the FDA and was included in
the phase III E2112 trial (NCT02115282) that started at
the beginning of 2014.
Figure 1 The PI3K/AKT/mTOR and the RAS/RAF/MEK/MAPK pathways. Phosphoinositide 3-kinase (PI3K) is a cytoplasmic lipid and protein
kinase recruited to the membrane by activated growth factor receptors, including human epidermal growth factor receptor 2 (HER2), epidermal
growth factor receptor (EGFR), and insulin-like growth factor 1 (IGF-1R). PI3K phosphorylates the 3′-hydroxyl group of phosphoinositides to
produce phoshatidylinositol-3,4,5-trisphosphate (PIP3), which is a second messenger that signals through AKT to activate several enzymes,
kinases, and transcription factors, including mammalian target of rapamycin (mTOR). The RAS/RAF/MEK/MAPK pathway converges with the
PI3K/AKT pathway and is now recognized as an alternative in mTOR activation. On the other hand, phosphatase and tensin homolog (PTEN)
catalyzes PIP3 dephosphorylation, acting as a negative regulator of its activity. In parallel with activation of growth factor receptors, estrogens can
activate nuclear estrogen receptors (ERs) (genomic pathway) or ERs on the membrane (non-genomic pathway). Membrane-associated ER binds to
PI3K and activates molecules such as AKT and RAS, crosstalking with the growth factor signaling pathways. Erk1/2, extracellular-signal-regulated
kinase 1/2; FOXO1, Forkhead box protein O1; MEK1/2, MAPK/Erk kinase 1/2; PIP, phosphatidylinositol phosphate; Raf, murine sarcoma viral oncogene
homolog; Ras, rat sarcoma viral oncogene homolog; RHEB, Ras homolog enriched in brain; RTK, receptor tyrosine kinase; TSC1/2, tuberous sclerosis
proteins 1 and 2.
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DNA amplification of HER2 gene is considered the main
mechanism of HER2 protein overexpression in HER2-
positive tumors. This subtype of tumors represents 20%
to 25% of all BC, shows HER2 protein overexpression by
IHC/FISH, and has been associated with poor disease-
free survival rates and increased chemo-resistance.
Within this clinically defined group, at least two differ-
ent molecular subtypes have been identified. About 50%
of clinically HER2-positive tumors express the HER2-
enriched mRNA subtype, whereas the rest express pre-
dominantly the luminal mRNA subtype. HER2-enriched
tumors show significantly higher expression of several
receptor tyrosine kinases, including FGFR4, epidermalgrowth factor receptor (EGFR), HER2 itself (80%), and
genes within the HER2 amplicon (that is, GRB7). On the
other hand, the luminal mRNA subtypes show higher
expression of the luminal signature, including GATA3,
BCL2, and ESR1. In HER2-enriched tumors, the main
somatic mutations were TP53 mutations (72%) and
PIK3CA mutations (39%), whereas GATA3 mutations
were observed only in luminal subtypes [17,20].
The HER family consists of four human EGFRs. Each
member of the HER family has identified ligands, with
the exception of HER2. Ligand binding to extracellular
domains promotes homo- or hetero-dimerization of
these receptors and promotes their intrinsic tyrosine
kinase activity. In this way, the dimerization triggers
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PI3K/AKT/mTOR, RAS/RAF/MEK/MAPK, and STAT
pathways. The development of trastuzumab has signifi-
cantly improved the prognosis of patients with HER2-
positive BC, but unfortunately a number of patients still
develop resistance and progressive disease. Several
mechanisms of resistance to trastuzumab have been
identified: impaired access to HER2 by expression of
extracellular domain-truncated HER2 (p95 HER2) or
overexpression of MUC4; alternative signaling from
IGF-1R, other HER family members, or MET; loss of
downstream controllers (PTEN and p27); and activation
of downstream signaling pathways (PI3K-Akt, MEK,
MAPK, and mTOR) [27].
In the last few years, several therapeutic strategies for
overcoming trastuzumab resistance have been devel-
oped, including lapatinib, pertuzumab, and trastuzumab-
DM1 (Table 4). These agents act by different mechanisms
on the HER2 protein and, in pre-clinical and clinical
models, have been shown to be effective even in
trastuzumab-resistant cells [28]. Future research should be
directed to identify biomarkers that could help to choose
which HER2-targeted therapy should be preferred. For
instance, lapatinib is a dual HER1 (EGFR) and HER2
tyrosine kinase inhibitor and acts on the intracellular
ATP-binding site of the kinase domain of the receptor.
Additional studies are needed to clarify whether tumor
cells with extracellular domain-truncated HER2 or with
alternative signaling from EGFR could benefit from the
mechanism of action of lapatinib. In these cases, reverse-
phase protein microarray (RPPA) and next-generation
sequencing (NGS) tests could be used as clinical diagnos-
tic assays to study HER2 protein status or alterations
within the signaling pathways, guiding treatment decision-
making. Moreover, in a subanalysis of the EMILIA trialTable 4 Biologic anti-HER2 agents approved for breast cance
Agent Approval Mechanism of action
Trastuzumab 1998 Humanized monoclonal antibody against th
domain of HER2. It triggers HER2 internaliza
degradation.
Lapatinib 2006 Dual inhibitor of the intracellular tyrosine ki
of both HER1 (EGFR) and HER2.
Pertuzumab 2012 Humanized monoclonal antibody against th
dimerization domain of HER2. It blocks the
heterodimerization of HER2 with other HER
T-DM1 2013 Trastuzumab-like activity.
Targeted intracellular delivery of cytotoxic e
BC, breast cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal(NCT00829166) [29], HER2 mRNA analysis by quantita-
tive reverse transcriptase-polymerase chain reaction and
the PIK3CA mutational status were analyzed on tumor
tissues. Cases expressing higher levels of HER2 mRNA
showed better OS from T-DM1, whereas PIK3CA muta-
tional status was not demonstrated to predict outcomes in
patients receiving T-DM1. On the other hand, in the
group receiving lapatinib and capecitabine, HER2 mRNA
was not demonstrated to influence outcomes, whereas pa-
tients with mutated PIK3CA status showed shorter me-
dian PFS and OS [30]. In conclusion, future research is
necessary to investigate BC cells at the molecular level in
order to select genomic and proteomic tools that could
guide targeted treatment choices.
Other potential strategies for overcoming trastuzumab
resistance include PI3K/AKT/mTOR pathway inhibitors,
HER2 vaccines, inhibitors of alternative signaling mole-
cules (IGF-1R and MET), ertumaxomab, and defucosy-
lated trastuzumab. Moreover, dual inhibition of HER2,
combining more monoclonal antibodies against the
HER2 extracellular domain, could be another effective
approach to treat trastuzumab-refractory HER2-positive
tumors.
In the last few years, the inhibition of heat shock pro-
tein 90 (Hsp90) has emerged as an attractive approach
in order to overcome trastuzumab resistance. Hsp90 is a
ubiquitous molecular chaperone fundamental for correct
folding and maturation of numerous cellular proteins.
Inhibition of the Hsp90 chaperone cycle leads to protein
ubiquitination and subsequent degradation by the prote-
asome. Because Hsp90 client proteins are frequently
products of oncogenes, Hsp90 may represent an import-
ant target in cancer therapy. Moreover, because Hsp90
protects cells from stress-induced damage, Hsp90 in-
hibitors could sensitize cells to cytotoxic agents andr treatment
Indications
e extracellular
tion and
Adjuvant BC
Metastatic BC
(from the first line)
nase domains Metastatic BC
(after prior anthracycline, taxane, and trastuzumab)
e extracellular
family.
Neoadjuvant BC
(with trastuzumab and docetaxel in locally advanced,
inflammatory, or early stage BC -either >2 cm or
node-positive)
Metastatic BC
(with trastuzumab and docetaxel for first-line therapy)
Metastatic BC (after the first line or in first line if
trastuzumab-resistance)mtansine.
growth factor receptor 2.
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vestigation in several clinical trials and have shown early
promising results in defined molecular subgroups of solid
tumors such as the HER2-positive BC [31]. HER2 is one
of the most sensitive client proteins to Hsp90 inhibition
and thus in the absence of Hsp90 activity HER2 is subject
to proteolysis, and drugs that target HER2 can be more ef-
fective. To date, promising results in terms of objective
tumor response have been observed with tanespimycin in
combination with trastuzumab in patients progressing on
trastuzumab (NCT00773344) [32] and more recently with
single-agent ganetespib in trastuzumab-refractory HER2-
positive tumors and TNBC (NCT01677455) [33].
Subtypes of triple-negative breast cancer and
p53 mutations
TNBC constitutes about 15% to 20% of all BC and is
clinically defined by the absence of ER and PR positivity
and the lack of HER2 overexpression by IHC. This het-
erogeneous group of tumors is more aggressive, with
higher rates of relapse and worse OS. The basal-like
tumor represents a specific group characterized by the
expression of genes found in normal basal/myoepithelial
breast cells, including high-molecular-weight basal cyto-
keratins (CK5/6, CK14, and CK17) or EGFR or both. For
years, the relationship between TNBC and basal-like tu-
mors has been controversial. However, not all TNBCs
are identified as basal-like tumors by gene expression,
and not all basal-like tumors are clinically TNBC; there-
fore, these two terms may not be considered synonym-
ous. In 2011, Lehmann and colleagues [34] identified six
different subtypes within TNBC by performing RNA
microarray analyses: two basal-like (BL1 and BL2), an
immunomodulatory (IM), a mesenchymal (M), a mesen-
chymal stem-like (MSL), and a luminal androgen recep-
tor (LAR) subtype. BL1 and BL2 subtypes heavily
express cell cycle and DNA damage response genes
(ATR/BRCA), and representative cell lines respond par-
ticularly to anti-mitotic and DNA-damaging agents, such
as platinum agents. In particular, the poly (ADP-ribose)
polymerase (PARP) family of enzymes, the DNA damage
response kinase ATR and its effector kinases CHEK1/2,
and the regulator of the G2 checkpoint WEE1 kinase
represent attractive pharmacological targets for radio-
sensitization and chemosensitization in these cells. Sev-
eral ATR, CHEK1/2, and WEE1 inhibitors are currently
under evaluation in phase I/II trials in TNBC, and a
number of PARP inhibitors are already included in phase
III studies. On the other hand, the IM subtype is highly
enriched in immune cell signaling, but it is still unclear
whether this genetic profile is reflective of cancer cells
or stromal immune infiltrate. M and MSL subtypes ex-
press genes involved in epithelial-mesenchymal transi-
tion (EMT), motility, and cell differentiation pathways,and its representative cell lines respond to PI3K/mTOR
inhibitors and dasatinib. Moreover, the MSL subtype is
enriched for mesenchymal stem cell-associated genes.
Finally, the LAR subtype expresses luminal signature
and androgen receptor (AR) signaling. LAR subtypes are
associated with better OS, and a recent phase II trial of
bicatulamide in AR-positive TNBC (NCT00468715) re-
ported a 6-month clinical benefit rate of 19% with a me-
dian PFS of 12 weeks, showing proof of principle for the
effectiveness of minimally toxic androgen blockade in
this subgroup of patients [35]. Currently, enzalutamide
and abiraterone are also under evaluation in phase II
studies in this select subset of patients.
Previous evaluations of gene expression profiles in
TNBC had led to the identification of another subgroup
named claudin-low and characterized by the absent
expression of luminal differentiation markers, high en-
richment for EMT markers, immune response genes,
and cancer stem cell (CSC)-like features [36]. However,
Lehmann and Pietenpol [37] observed that most of the
tumors classified as claudin-low are composed of M and
MSL subtypes, and concluded that the classification into
basal-like and non-basal-like subtypes oversimplifies the
molecular heterogeneity of TNBC. A comprehensive
classification of TNBC in molecular subtypes has the po-
tential to guide treatment decision-making and future
clinical trials investigating targeted therapies.
TP53 mutations are the most frequent clonal aberra-
tions in basal-like tumors (80%), but the loss of TP53
function, through gene mutations or dysfunctions in the
TP53 pathway, occurs within almost all basal-like tu-
mors. TP53 is a tumor-suppressor gene that, after the
activation by oncogenic stress signals, promotes either
cell cycle arrest and DNA repair or cell apoptosis. The
activity of TP53 is achieved by downstream targets
(p21), indirect targets (PTEN), cell cycle regulation
proteins (Chk1 and Chk2), and DNA repair proteins
(PARP-1 and BRCA-1). Moreover, the TP53 pathway is
influenced by prolyl isomerise 1, which is responsible for
post-translational modifications and histone acetylation,
which applies epigenetic modifications to the TP53 gene.
Mutated TP53 represents a potential target for TNBC
treatment but this approach remains a challenge on sev-
eral fronts since our knowledge of the TP53 pathway is
still largely incomplete and the heterogeneity of TNBC
comprises different behavior even among the subgroups
showing aberrant TP53 function [38]. In addition to loss
of TP53, loss of RB1 and BRCA1 functions are common
basal-like features. PIK3CA is the next most commonly
mutated gene (9%). However, interferences in PI3K path-
way activity are even more frequent in basal-like tumors
and include loss of PTEN and INPP4B. Furthermore, in
basal-like cancers, many of the elements of the PI3K/
AKT/mTOR and RAS/RAF/MEK/MAPK pathways were
Toss and Cristofanilli Breast Cancer Research  (2015) 17:60 Page 8 of 11amplified, including PIK3CA (49%), KRAS (32%), BRAF
(30%), and EGFR (23%) [17].
To date, on these molecular bases, many agents have
been included in clinical trials for patients with TNBC.
In particular, cabozantinib, a MET-, VEGFR2-, and RET-
targeted tyrosine kinase inhibitor, is under evaluation in
a phase II trial (NCT01738438). OTX015 and TEN-010
are bromodomain and extra-terminal domain (BET) bro-
modomain inhibitors that can inactivate the expression
of oncogenes such as Myc. These novel epigenetic mod-
ulators of gene expression are included in phase I trials
for patients with TNBC and solid tumors.
Breast cancer heterogeneity
BC represents a heterogeneous disease at the population
and single-cell level. Cancer cells within the same tumor
can exhibit different genotypes as well as phenotypes. In
the last decade, the development of NGS methods pro-
vided fundamental insight into the genetic intra-tumor
heterogeneity, and different models have been proposed
to explain the origins of this phenomenon. The first
model, proposed by Nowell in 1976, suggests that tumor
masses are caused by the expansion of one (monoclonal)
or multiple (polyclonal) cellular clones [39]. In the CSC
model, some precursor cells give rise to a different sub-
population of cells within the tumor with a hierarchical
arrangement. Lastly, in the mutator hypothesis, tumor
mass develops because of the gradual and random accu-
mulation of genetic mutations, causing a wide range of
diversity [40].
In the last few years, a plastic CSC model has been de-
veloped. The emerging CSC model suggests that cancer
initialization, progression, and metastasization are driven
by a specific subpopulation of tumor cells (named CSCs)
that express two fundamental characteristics: the cap-
acity for self-renewal and the ability to efficiently recon-
stitute differentiated tumors. These cells are associated
with phenotypic plasticity with the acquisition of pecu-
liar mesenchymal characteristics during specific phases
of the metastatic process. The EMT is a latent embry-
onic process that, when aberrantly activated in cancer
cells, promotes the reprogramming of epithelial cancer
cells toward a mesenchymal motile phenotype with mi-
gratory and invasive capacities and thus metastatic po-
tential [41]. EMT is a highly dynamic process that is
represented by several steps and multiple intermediate
states and that contributes to increase the cancer hetero-
geneity and plasticity. The transition is induced by sev-
eral extracellular stimuli, including different growth
factors (EGF, PDGF, and TGFβ), Hedgehog (Hh), Wnt/
β-catenin, Notch, and components of the extracellular
matrix and cellular stress conditions such as hypoxia. In
addition to migratory and invasive capabilities, induction
of EMT showed the ability to generate cells that exhibitmolecular and functional stem-like characteristics, lead-
ing to the expression of stem-cell markers such as the
CD44+/CD24− antigenic phenotype combined to the ex-
pression of ALDH-1. According to this hypothesis, tu-
mors can originate from the transformation of normal
adult tissue stem cells or from more differentiated pro-
genitors that have acquired stem-like capabilities [42].
On the other hand, disseminated cancer cells can per-
form a mesenchymal-epithelial transition reverting to an
epithelial phenotype in order to adhere and proliferate at
distal sites [43].
This clonal heterogeneity confers greater resistance to
selective environmental pressures and mostly to chemo-
therapy and radiation therapy [44]. As a matter of fact,
high-grade tumors, typically the basal-like and triple-
negative subtypes, showed the highest levels of genetic
diversity and the highest number of cells that express
molecular signatures characteristic of EMT, and thus
they are associated with worse clinical outcomes [45].
On this basis, CSCs may represent an attractive and
promising target for the development of future drugs. In
particular, novel therapeutic options are directed to
inhibit the pathways regulating the growth, survival,
and self-renewal of CSCs, including the Notch, Wnt/
β-catenin, Hh, and PI3K pathways (Figure 2) [46].
Akt represents a central hub in the Wnt/β-catenin and
PI3K signaling pathways. Pharmacological inhibition of
Akt may reduce tumor growth and regulate malignant
stem cells [47]. Notch signaling is an evolutionarily con-
served pathway that mediates communication between
adjacent cells and plays both oncogenic and tumor-
suppressor roles in various malignancies. Gamma-
secretase inhibitors represent an attractive therapeutic
option for the inhibition of the Notch pathway and are
currently under investigation in clinical trials for Alzhei-
mer’s disease, T-cell acute lymphoblastic leukemia, and
BC [46]. Furthermore, Harrison and colleagues [48] ob-
served that Notch4 signaling activity was notably higher
than Notch1 signaling activity in stem cell-enriched
cell populations, suggesting that selective inhibition
of Notch4 could be more effective and potentially less
toxic.
Finally, several cytokines have been shown to be in-
volved in the maintenance of CSCs, including interleu-
kin (IL)-6 and IL-8. In particular, CXCR1/2, the receptor
of IL-8, has been found to be overexpressed in cancer
cells expressing the stem cell marker ALDH [49]. The
interaction between CXCR1/2 and IL-8 increases CSC
self-renewal; thus, CXCR1/2 blockade may represent an-
other attractive target. Moreover, Singh and colleagues
[50] recently observed an interaction between the
CXCR1/2 signaling and the HER2 pathway, suggesting
that HER2-blocking agents might synergize with
CXCR1/2 inhibitors in targeting the CSCs. The clinical
Figure 2 Molecular pathways regulating breast cancer stem cells (CSCs). Akt represents a central hub in the Wnt/β-catenin and phosphoinositide
3-kinase (PI3K) signaling pathways. Upstream of Akt is the phosphatase and tensin homolog (PTEN) tumor suppressor. Loss of PTEN results in Akt
activation and thus the activation of the Wnt/β-catenin pathway through the Akt-mediated phosphorylation of glycogen synthase kinase 3-beta
(GSK3-β) and nuclear translocation of β-catenin. Through autocrine, juxtacrine, and paracrine mechanisms, secreted Hedgehog (Hh) interacts with
the 12 trans-membrane Patched 1 (PTCH) receptor, de-repressing the 7 trans-membrane Smoothened (SMO) protein and allowing its translocation
to the cilia. Activated SMO promotes a signaling cascade resulting in activation of the GLI transcription factors and thus in upregulation of genes
that regulate cellular differentiation, proliferation, and survival. Four different Notch receptors (Notch 1, Notch 2, Notch 3, and Notch 4) interact with
five ligands (Delta-like 1, Delta-like 3, Delta-like 4, Jagged 1, and Jagged 2) expressed on neighboring cells. The interaction between ligand and the
extracellular domain of Notch receptor triggers the cleavage by gamma-secretase and the release of the Notch intracellular domain (NICD), which
translocates into the nucleus and associates with transcription factors regulating Notch target genes expression. The interaction between CXCR1/2
and interleukin (IL)-8 increases CSC self-renewal. HER2 regulates CSCs through the activation of the Wnt/β-catenin pathway, and loss of PTEN results
in the downstream activation of the Wnt/β-catenin signaling. The activation of an inflammatory loop involving IL-6 and IL-8 has been shown to
determine PTEN suppression and thus the resistance to HER2-targeting agents. IkB, kinase B inhibitor; p50, protein 50; Src, rous sarcoma oncogene
cellular homolog; Stat3, signal transducer and activator of transcription 3.
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apies in the future management of patients with BC
present challenges but also the opportunity to modify
the natural history of the most aggressive forms of this
disease.
Immune pathway
The immune system could play a role in the effective-
ness of conventional anticancer treatments. Higher levels
of tumor-infiltrating lymphocytes (TIL) have beenassociated with a higher rate of pCR after NACT,
and post-chemotherapy TIL presence has been linked with
better outcomes in patients who did not obtain pCR after
neoadjuvant paclitaxel. Especially in TNBC, high levels of
TIL in residual disease after NACT represent a strong
prognostic factor and thus may help to identify patients
who, despite residual disease, will have good outcome.
Moreover, the conversion from originally low-TIL tumors
into high-TIL tumors after NACT has been associated
with a significant improvement in OS, suggesting that
Toss and Cristofanilli Breast Cancer Research  (2015) 17:60 Page 10 of 11chemotherapy could induce an antitumor immune re-
sponse [51,52]. Also in the adjuvant setting, high TIL level
has been significantly associated with decreased distant
recurrence rates in primary TNBC treated with conven-
tional adjuvant chemotherapy [53].
The involvement of the immune system has been con-
firmed even in trastuzumab antitumor activity. Recent
evidence has demonstrated that TIL could predict effi-
cacy of trastuzumab, since they increase its benefit in
HER2-positive tumors [53]. These results suggest that
immune infiltration may represent a useful parameter to
stratify patients eligible for treatments, provide evidence
for the development of immune-mediated therapies
in BC, and may represent a surrogate for detection of
NACT efficacy.
Conclusions
The use of advanced diagnostics in BC has increased our
understanding of disease biology and is currently applied
to clinical practice. Evaluation of standard biomarkers
(ER, PR, and HER2) in primary BC can be supplemented
by molecular profiling with significant information on
disease subtyping, which constitutes prognostic and pre-
dictive data that can help in treatment planning. More-
over, the application of NGS and RPPA in the metastatic
setting holds promise in further advancing precision
medicine. Patients with a BC diagnosis can now benefit
from selection of a number of novel targeted therapies
that are either FDA-approved or under development and
that have already translated to significant improvement
in survival for this disease. Unfortunately, approximately
40,000 women a year still die of metastatic disease in the
United States, suggesting that we have made limited
strives in investigating and treating metastasis. The inte-
gration of CSC-targeted therapies and immune therapies
in future combination regimens holds promise in address-
ing this unexplored area of clinical research and likely cur-
ing a larger proportion of women with metastatic BC.
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